Previously indicated for once-daily administration at bedtime, Lantus (an insulin glargine injection marketed by Aventis) has received FDA approval for flexible administration at any time of the day. The new approval means that Lantus can be administered once daily at any time, but the time should be the same time each day.
Lantus, the only basal insulin analogue that provides 24-hour glucose-lowering activity with one injection, is unique because it has no pronounced peak. It exhibits similar absorption and consistency of action regardless of the injection site. Possible adverse events include hypoglycemia, lipodystrophy, and skin reactions.
Don't dilute Lantus or mix it with any other solution.
Copyright Springhouse Corporation Nov 2003
Provided by ProQuest Information and Learning Company. All rights Reserved